Member Info for Krustysmegma

As the merger completes, the name has now changed to Barratt Redrow PLC and the new ticker BTRW. This site, and others, haven't caught up yet but no daily updates on here, see you all on the other side.

...from today's magazine, originally tipped SUPR in March:

"We believe Supermarket Income REIT will reward patient investors, although while an 8% yield is nice we do also expect the share price to get a shimmy on as we approach retail’s ‘golden quarter’.

Commercial property valuations should rise as interest rates fall, which will give added support to the stock price, and we can even see the case for the discount to NAV (net asset value) narrowing which would be a bonus."

By definition, their positions are "Non-Executive". They'll be able to provide support & advice to the main Board directors, and may be able to do a bit of glad-handing to help open one or two doors that would otherwise remain closed, but they won't be negotiating deals. That's the job of the Executives on the Board, and their support staff.

That will happen on Thursday, not tomorrow. XD 3/10/24.

Suppress any rise in the SP? I guess half a million £ loss should do it.

I'm guessing you'll be able to add a couple of noughts to the turnover figure this year tariq.

Wow, 20m shares = less than £3k. Tempting to buy 2-300,000,000 except it's screaming consolidation, placing & PI wipeout.

Excellent news!

Citigoup raises 3i target to 4140. Now THAT'S more like it! Already sniffing 3400...

Interesting Gus, quite similar to my own position on this really. There isn't a right or wrong answer, and hopefully whichever way it goes will be transformational for many holders here.

I see, thanks Aber. £3 - £5 would be life-changing for me so it would be churlish to say it doesn't appeal, but if 1801 developed into the first-line treatment for psoriasis in 10 years time, given the size of the market, I believe we would look back on it & think we'd given it away at that price. Interesting to get some context though, thanks again.

OK thanks Gus

Aber, I'm very much in the DIY camp so I'm intrigued to know what the appeal of an early-stage deal is? Is it to avoid the costs of clinical trials? Or avoid the risk of failure? Or getting out quicker with a decent return? Maybe all of the above?

I don't know which is the right way forward, but for me if they can get 1801 through P2a successfully within existing resource, or with relatively little additional funding, that opens the door to a much bigger payday and still with the promise of 1802 etc. to follow. Just intrigued to know why this is so much less appealing to those (apparently significant numbers) who are looking for a deal now.

That didn't take long, another positive update this morning should keep the pot boiling. I know this is all about Action but good to see one or two other portfolio companies coming back into play.

Anyone else seeing the LSE spyware (small red box, top-left of the page)? Monitoring every page visited & who knows what else.

Deadline for tendering with HL 9.00am Tuesday 24th Sept.

Corporate action now available on HL, you should have received a secure message to confirm. The only difference appears to be the % allocation may differ as the shares are held by HL but I can't see how it can be dramatically different.

Hope The Oak Bloke is impressed by the report. I'm not.

Signing off with a blatant de-ramp, class!

Still nothing yet Kenny, will check again in the morning.